211 related articles for article (PubMed ID: 15566355)
21. Antisense therapy of hematologic malignancies.
Cotter FE
Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
[TBL] [Abstract][Full Text] [Related]
22. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
23. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Herbst RS; Frankel SR
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
[TBL] [Abstract][Full Text] [Related]
24. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
25. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
30. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
33. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
35. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
36. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
Smith MR; Jin F; Joshi I
Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
38. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
Schlagbauer-Wadl H; Klosner G; Heere-Ress E; Waltering S; Moll I; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2000 Apr; 114(4):725-30. PubMed ID: 10733680
[TBL] [Abstract][Full Text] [Related]
40. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
